Approximately 15–20% breast cancer patients have amplification of the human epidermal growth factor receptor-2 (HER2) expression, which is proved to be associated with aggressive biological behavior and poor clinical outcomes (3, 4). The gene discussed is ERBB2; the disease is breast carcinoma.